Torsdag 25 December | 05:41:52 Europe / Stockholm

Prenumeration

Kalender

Est. tid*
2026-11-12 08:00 Kvartalsrapport 2026-Q3
2026-08-13 08:00 Kvartalsrapport 2026-Q2
2026-05-07 N/A Årsstämma
2026-05-07 08:00 Kvartalsrapport 2026-Q1
2026-02-27 08:00 Bokslutskommuniké 2025
2025-12-22 - Extra Bolagsstämma 2025
2025-11-20 - Kvartalsrapport 2025-Q3
2025-08-12 - Kvartalsrapport 2025-Q2
2025-05-09 - X-dag ordinarie utdelning VIVE 0.00 SEK
2025-05-08 - Årsstämma
2025-05-08 - Kvartalsrapport 2025-Q1
2025-02-20 - Bokslutskommuniké 2024
2024-11-21 - Kvartalsrapport 2024-Q3
2024-08-22 - Kvartalsrapport 2024-Q2
2024-05-24 - X-dag ordinarie utdelning VIVE 0.00 SEK
2024-05-23 - Årsstämma
2024-05-23 - Kvartalsrapport 2024-Q1
2024-02-22 - Bokslutskommuniké 2023
2023-11-16 - Kvartalsrapport 2023-Q3
2023-08-24 - Kvartalsrapport 2023-Q2
2023-05-26 - X-dag ordinarie utdelning VIVE 0.00 SEK
2023-05-25 - Årsstämma
2023-05-25 - Kvartalsrapport 2023-Q1
2023-02-23 - Bokslutskommuniké 2022
2022-11-17 - Kvartalsrapport 2022-Q3
2022-08-25 - Kvartalsrapport 2022-Q2
2022-05-27 - X-dag ordinarie utdelning VIVE 0.00 SEK
2022-05-25 - Årsstämma
2022-05-25 - Kvartalsrapport 2022-Q1
2022-02-23 - Bokslutskommuniké 2021
2021-11-17 - Kvartalsrapport 2021-Q3
2021-08-25 - Kvartalsrapport 2021-Q2
2021-05-28 - X-dag ordinarie utdelning VIVE 0.00 SEK
2021-05-25 - Kvartalsrapport 2021-Q1
2020-09-10 - X-dag ordinarie utdelning VIVE 0.00 SEK
2020-09-09 - Årsstämma
2020-06-18 - Bokslutskommuniké 2020
2020-05-14 - Extra Bolagsstämma 2020
2020-03-27 - Kvartalsrapport 2020-Q3
2019-12-30 - Kvartalsrapport 2020-Q2
2019-11-06 - Extra Bolagsstämma 2019
2019-09-27 - X-dag ordinarie utdelning VIVE 0.00 SEK
2019-09-26 - Årsstämma
2019-09-26 - Kvartalsrapport 2020-Q1
2019-07-12 - Bokslutskommuniké 2019
2019-03-01 - Kvartalsrapport 2019-Q3
2018-11-30 - Kvartalsrapport 2019-Q2
2018-09-25 - Årsstämma
2018-09-05 - X-dag ordinarie utdelning VIVE 0.00 SEK
2018-08-31 - Kvartalsrapport 2019-Q1
2018-06-08 - Bokslutskommuniké 2018
2018-03-02 - Kvartalsrapport 2018-Q3
2017-12-01 - Kvartalsrapport 2018-Q2
2017-09-26 - X-dag ordinarie utdelning VIVE 0.00 SEK
2017-09-25 - Årsstämma
2017-09-01 - Kvartalsrapport 2018-Q1
2017-06-08 - Bokslutskommuniké 2017
2017-03-03 - Kvartalsrapport 2017-Q3
2016-12-02 - Kvartalsrapport 2017-Q2
2016-11-21 - Extra Bolagsstämma 2016
2016-09-27 - X-dag ordinarie utdelning VIVE 0.00 SEK
2016-09-26 - Årsstämma
2016-09-02 - Kvartalsrapport 2017-Q1
2016-06-03 - Bokslutskommuniké 2016
2016-03-03 - Kvartalsrapport 2016-Q3
2015-12-03 - Kvartalsrapport 2016-Q2
2015-09-29 - X-dag ordinarie utdelning VIVE 0.00 SEK
2015-09-28 - Årsstämma
2015-09-03 - Kvartalsrapport 2016-Q1
2015-06-04 - Bokslutskommuniké 2015
2015-03-05 - Kvartalsrapport 2015-Q3
2014-12-04 - Kvartalsrapport 2015-Q2
2014-09-30 - X-dag ordinarie utdelning
2014-09-29 - Årsstämma
2014-09-05 - Kvartalsrapport 2015-Q1
2014-06-05 - Bokslutskommuniké 2014
2014-03-06 - Kvartalsrapport 2014-Q3
2013-12-05 - Kvartalsrapport 2014-Q2
2013-10-01 - X-dag ordinarie utdelning VIVE 0.00 SEK
2013-09-06 - Kvartalsrapport 2014-Q1
2013-06-07 - Bokslutskommuniké 2013
2013-03-13 - 15-7 2013
2013-03-01 - Kvartalsrapport 2012-Q3
2012-12-06 - Kvartalsrapport 2012-Q2
2012-09-25 - X-dag ordinarie utdelning VIVE 0.00 SEK
2012-09-24 - Årsstämma
2012-09-06 - Kvartalsrapport 2012-Q1
2012-06-14 - Bokslutskommuniké 2011
2012-03-08 - Kvartalsrapport 2011-Q3
2011-12-08 - Kvartalsrapport 2011-Q2
2011-10-03 - X-dag ordinarie utdelning VIVE 0.00 SEK
2011-09-30 - Årsstämma
2011-09-08 - Kvartalsrapport 2011-Q1
2011-06-10 - Bokslutskommuniké 2010
2010-12-09 - Kvartalsrapport 2010-Q2
2010-09-24 - Årsstämma
2010-09-09 - Kvartalsrapport 2010-Q1
2009-12-10 - Kvartalsrapport 2009-Q3

Beskrivning

LandSverige
ListaSmall Cap Stockholm
SektorHälsovård
IndustriBioteknik
Vivesto är verksamt inom läkemedelsbranschen och fokuserar på utveckling av innovativa behandlingar för svåra sjukdomar inom onkologi. Bolaget forskar på nya terapier som kan förbättra patientresultat och livskvalitet. Verksamheten är global med en huvudsaklig närvaro i Europa och Nordamerika. Vivesto grundades 1988 och har sitt huvudkontor i Uppsala.

Intresserad av bolagets nyckeltal?

Analysera bolaget i Börsdata!

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

2025-12-22 10:30:00

At the Extraordinary General Meeting in Vivesto AB (“Vivesto” or the “company”) held on 22 December 2025, the following resolutions were passed. All resolutions were in accordance with the proposals, described in detail in the general meeting documents which are available on the company’s website, www.vivesto.com.

Resolution on amendments of the articles of association and on approval of the Board of Directors’ resolution on a new issue of shares with preferential rights for existing shareholders
It was resolved to approve the Board of Directors’ resolution on 20 November 2025 on a new issue, with preferential rights for existing shareholders, of no more than 538,043,455 shares, entailing an increase in share capital of no more than SEK 53,804,345.5 (the ”Rights Issue”).

The right to subscribe for shares shall, with preferential rights for existing shareholders, be granted those who on the record date for the new issue on 5 January 2026 are registered as shareholders in the company. Each shareholder receives one (1) subscription right for each (1) share held. Each (1) subscription right entitles to subscription for one (1) share. The subscription price is SEK 0.10 per share. Subscription for shares shall be made during the period from and including 8 January 2026 up to and including 22 January 2026. The Board of Directors is entitled to extend the subscription period.

For the Rights Issue, the detailed terms and conditions set out in the general meeting documents available on the company’s website and in the information document that will be published in connection with the Rights Issue shall apply.

The resolution was made in fulfilment of the majority requirement set by the Swedish Securities Council as a condition for the validity of the exemption from the mandatory bid obligation granted to Per Arwidsson and related parties in relation to Arwidsro Investment AB’s guarantee undertaking regarding the Rights Issue.

In order to enable the Rights Issue, it was resolved to amend the limits for the share capital and the number of shares in the articles of association.

Resolution on approval of guarantee undertaking
It was resolved to approve the entry into an agreement with Arwidsro Investment AB (“Arwidsro Investment”), under which Arwidsro Investment provides a so-called top guarantee undertaking in the Rights Issue (the “Top Guarantee Undertaking”). The Top Guarantee Undertaking entails that Arwidsro Investment undertakes to subscribe and pay for shares in the Rights Issue in addition to its pro rata share in the event that the Rights Issue is not fully subscribed with or without exercise of subscription rights, including the subscription commitments and other guarantee undertakings. The amount guaranteed under the Top Guarantee Undertaking amounts to SEK 15 million.

Resolution on authorization for the Board of Directors to resolve on a new issue of shares to guarantors
It was resolved, in order to enable new issue of shares as guarantee commission to the parties that have entered into guarantee undertakings (the “Guarantors”) in the Rights Issue, to authorize the Board of Directors to, on one or several occasions during the period up until the next Annual General Meeting, resolve on a new issue of shares to the Guarantors, with deviation from the shareholders’ preferential rights. The number of shares that may be issued under the authorization may not exceed the number of shares corresponding to the agreed guarantee commission that the company is to pay to the Guarantors. Payment may be made by set-off, or otherwise with conditions.

Further information on the proposals approved by the Extraordinary General Meeting is set out in the general meeting documents available on the company’s website.